Serina Therapeutics (NYSEAMERICAN:SER) Stock Price Down 1.8% – What’s Next?

Shares of Serina Therapeutics, Inc. (NYSEAMERICAN:SER) were down 1.8% during mid-day trading on Friday . The company traded as low as $2.64 and last traded at $2.80. 75,950 shares traded hands during trading, an increase of 69% from the average daily volume of 44,893 shares. The stock had previously closed at $2.85.

Wall Street Analyst Weigh In

Separately, BTIG Research began coverage on Serina Therapeutics in a report on Wednesday, July 1st. They issued a “buy” rating and a $8.00 price target on the stock. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $8.00.

Serina Therapeutics Stock Down 1.8%

The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.24. The firm’s 50 day simple moving average is $2.09 and its 200-day simple moving average is $2.02. The stock has a market capitalization of $42 million, a price-to-earnings ratio of -1.48 and a beta of 1.11.

Serina Therapeutics (NYSEAMERICAN:SER) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.55) EPS for the quarter.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.